As measured by its current market cap, Vertex Pharmaceuticals ( VRTX , Financial) would be the most expensive among the 10 companies identified by Fierce Biotech as the top M&A targets, with Adaptimmune Therapeutics plc ( ADAP , Financial) being the cheapest.